10.03.24 -- The Impact Of Novo Holdings' Catalent Acquisition On Biopharma

The manufacturing process for autologous therapies is complex and highly customized, requiring well-orchestrated transport, careful planning, and tight control of many discrete and manual processing steps.

Watch to gain expert insights into the critical steps needed to confidently advance your AAV gene therapy from concept to successful commercialization.

Help transform the development of advanced therapies by embracing a new standard that delivers quality, speed, and cost-efficiency without compromise.

Industry experts answer attendee questions from a recent webinar about sustainability concerns surrounding oligonucleotide manufacturing.

Explore a demonstration of a scalable, high-yield triple-transfection rAAV platform's flexibility and efficiency, enabling gene therapy production with robust performance metrics and streamlined processes.

CDMOs are playing a critical role in the global effort to prepare for future pandemics. Learn how innovative strategies and flexible platforms are helping to ensure a swift and effective response plan.

Review the demands for AAV manufacturing using a suspension process and the DOE-based strategy used to achieve a scalable process both in terms production and quality of AAV purified.

Low AAV productivity and lack of platform processes continue to increase AAV production costs. Consider this robust and scalable suspension manufacturing platform for AAV production.

See how supply chain solutions like BioServices can help companies mitigate risk to their overall supply chain while saving valuable capital for the research of their lifesaving therapies.